The diagnostic gains of repeat testing for Clostridium difficile by enzyme immunoassay and PCR (i.e., initial negative result followed by positive result) within a 7-day period were 1.9 and 1.7%, respectively. There is little value of repeat testing for C. difficile by enzyme immunoassay or PCR.
patients tested by EIA and 2,827 patients tested by PCR. The mean age of patients in both groups was 59 years (median ϭ 61 years), with ranges of 16 to 103 years for EIA and 16 to 97 years for PCR. Among the patients, 2,703 (46.7%) and 1, 306 (46.2%) tested by EIA and PCR, respectively, were men. Of 4,313 subjects with only a single test by EIA, 333 (7.7%) had positive results. For PCR, this group consisted of 2,384 subjects, among whom 297 (12.5%) had positive results.
The group of EIA patients tested only twice consisted of 792 subjects (13.7% of patients tested with EIA) (Table 1) . Six hundred eighty-three patients (11.8% of patients tested with EIA) had three or more EIA tests performed within 7 days (Tables 2 and 3) , and 605 (88.6%) had only negative results (Table 2) . Twenty (2.9%) patients had a negative result on the first test with subsequent positive results on the following tests ( Table 2 ). The remaining 58 (8.5%) patients had a positive first test followed by subsequent positive or negative tests (Table 3) .
Three hundred fifty-one patients were tested only twice by PCR (12.4% of patients tested by PCR) ( Table 4 ). There were 92 patients (3.2% of patients tested by PCR) who had three or more PCR tests performed within 7 days. In 85 (92.4%) cases, results of all tests were negative. There were no patients who had positive results following an initial negative test. For six patients (6.5%), the results switched from an initial positive to a subsequent negative result, while one patient (1.1%) demonstrated only positive results (Table 5) .
We compared the numbers of repeat EIA and PCR testing episodes where the result switched from being negative on the initial test to being positive over the course of multiple testing. We analyzed any patient who had two or more tests performed in 7 days, including all patients with exactly two tests and patients with three or more tests during this period. Of the 1,321 patients who had an initial negative EIA test, 25 (1.9%) were positive on the second test (95% CI, 1.2% to 2.7%), compared to 1.7% (95% CI, 0.7% to 3.5%) becoming positive for the 401 patients having an initial negative PCR test (P ϭ 1.0). We studied, to the best of our knowledge, the largest group of patients analyzed for assessment of repeat C. difficile testing ( Table 6 ) and demonstrated that the incremental yields of repeat testing by EIA and PCR are low and not statistically significantly different between the two tests. Several authors have suggested that it may be useful to test more than one stool specimen for C. difficile toxin by use of an immunoassay (1, 4, 11) ; this practice has been adopted widely in the clinical setting, including at our own institution. Nevertheless, there are limited data supporting this practice (Table 6 ). Since PCR is more sensitive than EIA (14), we expected to show a lower incremental yield of repeat testing for C. difficile via PCR versus EIA; this was not the case.
There are limitations to our study. EIA and PCR testing was done in sequential periods and consequently on different patient populations. The numbers of repeat tests performed varied between EIA and PCR, with 13.7% and 12.4% of the EIA and PCR groups, respectively, being tested just twice and 11.8% and 3.2% of the EIA and PCR groups, respectively, being tested three or more times (P Ͻ 0.001). The less frequent ordering of large numbers of PCR versus EIA tests may relate to laboratory practice changes made after implementation of PCR, allowing computer checking for repeated tests within 24 h and rejection of duplicate specimens. Positive We conclude that the diagnostic gains of repeat testing are equally low for PCR and EIA and that repeat testing for C. difficile should not be routine.
